Igor Bondarenko
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
Papers in
- Oncology 124
- Cancer Immunotherapy and Biomarkers 27
- HER2/EGFR in Cancer Research 26
- Lung Cancer Research Studies 24
- Cancer Treatment and Pharmacology 19
- Colorectal Cancer Treatments and Studies 16
- Neutropenia and Cancer Infections 14
-
- Lung Cancer Treatments and Mutations 32
- Advanced Breast Cancer Therapies 16
- Co-authors
- Martin Reck (8 shared papers)Filippo Guglielmo Maria de Braud (3 shared papers)Gunter Schuch (2 shared papers)P. Koralewski (2 shared papers)Angela Zubel (2 shared papers)Carsten Bokemeyer (2 shared papers)Anatoly Makhson (2 shared papers)Seock‐Ah Im (6 shared papers)
- Journals
- Annals of Oncology (76 papers)Journal of Clinical Oncology (22 papers)The Lancet Oncology (13 papers)European Journal of Cancer (10 papers)Clinical Cancer Research (10 papers)
- Partner nations
- United StatesUkraineRussia
In The Last Decade
Igor Bondarenko
228 papers receiving 35.3k citations
Igor Bondarenko's Hit Papers
Peers
Comparison fields: 5 of 149
- Oncology 21.2k
- Pulmonary and Respiratory Medicine 11.0k
- Cancer Research 3.4k
- Immunology 4.7k
- Hepatology 1.1k
Countries citing papers authored by Igor Bondarenko
This map shows the geographic impact of Igor Bondarenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Bondarenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Bondarenko more than expected).
Fields of papers citing papers by Igor Bondarenko
This network shows the impact of papers produced by Igor Bondarenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Bondarenko. The network helps show where Igor Bondarenko may publish in the future.
Co-authors
The 25 scholars most cited alongside Igor Bondarenko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 237 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Hit paper breakdown → | 2011 | 3746 |
| 2 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2691 |
| 3 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 2634 |
| 4 | Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1711 |
| 5 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Hit paper breakdown → | 2014 | 1551 |
| 6 | Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2016 | 1457 |
| 7 | Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 1355 |
| 8 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2015 | 1129 |
| 9 | Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Hit paper breakdown → | 2019 | 1048 |
| 10 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2018 | 948 |
| 11 | Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study Hit paper breakdown → | 2012 | 872 |
| 12 | RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer Hit paper breakdown → | 2011 | 858 |
| 13 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Hit paper breakdown → | 2014 | 773 |
| 14 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Hit paper breakdown → | 2011 | 665 |
| 15 | Weekly nab -Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial Hit paper breakdown → | 2012 | 650 |
| 16 | Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial Hit paper breakdown → | 2021 | 602 |
| 17 | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Hit paper breakdown → | 2017 | 536 |
| 18 | Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Hit paper breakdown → | 2012 | 528 |
| 19 | Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2020 | 516 |
| 20 | Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2010 | 515 |
About Igor Bondarenko
Igor Bondarenko is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 237 papers that have together received 36.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (32 papers), Cancer Immunotherapy and Biomarkers (27 papers), HER2/EGFR in Cancer Research (26 papers), Lung Cancer Research Studies (24 papers), Cancer Treatment and Pharmacology (19 papers), Colorectal Cancer Treatments and Studies (16 papers), Advanced Breast Cancer Therapies (16 papers) and Neutropenia and Cancer Infections (14 papers). The work is most often cited by research in Oncology (21.2k citations), Pulmonary and Respiratory Medicine (11.0k citations), Cancer Research (3.4k citations), Immunology (4.7k citations) and Hepatology (1.1k citations). Igor Bondarenko has collaborated with scholars based in United States, Ukraine and Russia. Frequent co-authors include Martin Reck, Filippo Guglielmo Maria de Braud, Gunter Schuch, P. Koralewski, Angela Zubel, Carsten Bokemeyer, Anatoly Makhson, Seock‐Ah Im, Dennis J. Slamon and Nicholas C. Turner. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, The Lancet Oncology, European Journal of Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.